Nanobiotix S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Conference call and webcast scheduled for thursday, april 25, 2024, at 8:00 am edt / 2:00 pm. cest conference call and webcast scheduled for thursday, april 25, 2024, at 8:00 am edt / 2:00 pm. cest

Paris and cambridge, mass., april 02, 2024 (globe newswire) -- nanobiotix (euronext : nano –– nasdaq: nbtx – the ‘‘company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced completion of the dose escalation part of a phase 1 study evaluating potential first-in-class radioenhancer nbtxr3 for patients with non-small cell lung cancer (“nsclc”) that cannot be treated by surgery (“inoperable”), and has come back (“recurrent”), whom have previously been treated with definitive radiation therapy and are amenable to re-irradiation. the phase 1 study (“study 2020-0123”) is being conducted by the university of texas md anderson cancer center (“md anderson”) as part of an ongoing strategic collaboration with nanobiotix.

Paris and cambridge, mass., march 06, 2024 (globe newswire) -- nanobiotix (euronext: nano –– nasdaq: nbtx – the ‘‘company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that company management will participate in fireside chats at the upcoming guggenheim healthy altitudes summit and the leerink partners global biopharma conference. please see below for details on each event.

Paris and cambridge, mass., jan. 31, 2024 (globe newswire) -- nanobiotix (euronext: nano –– nasdaq: nbtx – the ‘‘company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that laurent levy, co-founder of nanobiotix and chairman of the executive board, and bart van rhijn, chief financial officer, will participate in a fireside chat at the guggenheim 6th annual biotechnology conference on wednesday, february 7, 2024, at 3:00 pm et / 9:00 pm cet in new york, ny.

Paris and cambridge, mass., jan. 29, 2024 (globe newswire) -- nanobiotix (euronext : nano –– nasdaq: nbtx – the ‘‘company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in nanoray-312, an ongoing pivotal phase 3 study evaluating potential first-in-class radioenhancer nbtxr3 for elderly patients with head and neck cancer, resulting in a $20m milestone payment from strategic partner janssen pharmaceutica nv (“janssen”), a johnson & johnson company.

Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event.

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.

Nanobiotix S.A. (NASDAQ:NBTX ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Craig West - Senior Vice President of Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.

Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET

Nanobiotix S.A. (NASDAQ:NBTX ) Q2 2023 Earnings Conference Call September 27, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder & CEO Bart Van Rhijn - CFO Conference Call Participants Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C.

Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023

PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 4:00 PM EDT / 10:00 AM CEST.

Nanobiotix is an oncology-focused biotech aiming for its first drug approval, with a tripled value since the beginning of 2023. Their flagship molecule, NBTX3-RT, is showing promising results in enhancing the efficacy of radiotherapy for various solid tumors. A recent licensing agreement with Janssen provides significant funding and de-risking for Nanobiotix's next steps.

French biotechnology company Nanobiotix has entered into an agreement with J&J's wholly-owned medical research and pharmaceutical arm Janssen to license, co-develop and commercialize a drug to treat head and neck cancer tumours, sending the company's shares soaring.  The agreement relates to Nanobiotix's radioenhancer NBTXR3 which is being evaluated in a Phase 3 study for the treatment of patients with locally advanced head and neck cancer and for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for patients with metastatic cancers.